Zoetis Competitive Intelligence & Landscape

The company's core products and services encompass a wide range of animal health solutions, from diagnostics and pharmaceuticals to vaccines.

Zoetis emphasizes innovation, investing in research and development to meet current and future unmet needs in animal health. Their offerings are designed to address the diverse challenges faced by their target market, which includes pet owners, veterinarians, and producers in animal agriculture.

While the exact founding year as an independent entity is not specified on the homepage, Zoetis highlights a "legacy of nearly 75 years" in animal health, stemming from its origins as part of Pfizer's animal health division.

Zoetis became an independent company in 2013, having been the animal health division of Pfizer for decades prior [https://www.zoetis.com/our-company/our-story/history]. The company is led by an experienced executive team, with Kristin Peck serving as CEO [https://www.zoetis.com/our-company/our-story/executive-team/]. Information regarding the specific headquarters location and current precise employee count is not directly available on the provided homepage content, but it is implied to be a global operation with colleagues around the globe.

Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals [https://zoetis.com/]. This commitment defines their culture, which emphasizes being valued, included, supported, and proud. They are also deeply committed to sustainability through their "Driven to Care" approach, aiming to be the most sustainable animal health company and create a healthier world for all. This mission extends to their innovative solutions, designed to improve the health and well-being of animals, people, and the planet.

Zoetis offers a range of diagnostic products, including the Vetscan OptiCell™, a cartridge-based hematology analyzer, and Vetscan Imagyst®, an AI-powered analyzer providing multiple testing capabilities with rapid results [https://www.zoetis.com/products-and-science/diagnostics]. In terms of pricing, Zoetis Reference Laboratories has introduced OptimizeDx, a new flat-rate program designed to simplify the complex pricing and requirements often associated with veterinary diagnostic testing [https://cloud.mc.zoetis.com/optimizedx-campaign-landing-page]. This program aims to offer clear, consistent pricing for a comprehensive suite of clinical and anatomic pathology tests, covering most species.

Beyond diagnostics, Zoetis provides various products for pet care, including treatments like Cerenia Injectable and Convenia, with promotions such as a FREE Protect and Treat Toolkit available with certain purchases [https://cloud.mc.zoetis.com/protect-and-treat]. For farm animals, their extensive vaccine portfolio helps protect herd health and profitability for beef and dairy cattle, pigs, poultry, sheep, and fish [https://cloud.mc.zoetis.com/vaccines][https://www2.et.zoetis.com/content/en/pages/Products-and-Services/Farm-Animals.aspx]. They also offer genomic tools like SHEPHERD® for sheep producers, enabling informed decisions based on genetic merit [https://www.zoetis.com/products-and-science/products/shepherd].

The company's hiring patterns indicate a strategic focus on global expansion and continuous innovation in animal health.

Zoetis emphasizes recruiting individuals who are dedicated to their purpose of "nurturing our world and humankind by advancing care for animals" [https://www.zoetis.com/join-us]. This includes a significant presence in research and development, manufacturing, and supply chain management, ensuring they can meet the evolving needs of veterinarians, livestock producers, and pet owners worldwide.

Zoetis is also committed to nurturing new talent through its comprehensive Summer Intern Program, typically held from May to August. Openings for these internships are posted in the fall each year, offering students hands-on experience in a supportive and collaborative environment [https://www.zoetis.com/join-us/intern-at-zoetis]. Interns are required to be enrolled in a degree program, have completed at least one year of undergraduate studies with a 3.0 GPA or higher, and be authorized to work in the U.S. [https://www.zoetis.com/join-us/how-to-apply]. This program aligns with Zoetis' strategy of investing in future talent and cultivating a strong pipeline of professionals dedicated to animal health.

While specific layoff data is not available from the provided sources, the strong emphasis on open roles across commercial operations, research and development, and global markets, alongside a structured internship program, suggests a period of growth and strategic talent acquisition at Zoetis. The company's consistent recognition for its award-winning culture and support for employee careers further indicates a stable and supportive work environment [https://www.zoetis.com/join-us/life-at-zoetis].

The company's net income attributable to Zoetis has also shown healthy growth, from $2.114 billion in 2022 to $2.486 billion in 2024 [https://www.zoetis.com/_assets/pdf/corporate/zoetis-2024-annual-report.pdf], and further to $2.673 billion in 2025 [https://www.zoetis.com/_assets/pdf/corporate/zoetis-2025-annual-report.pdf]. Diluted earnings per share (EPS) have similarly risen, from $4.49 in 2022 to $5.47 in 2024 [https://www.zoetis.com/_assets/pdf/corporate/zoetis-2024-annual-report.pdf], reaching $6.02 in 2025 [https://www.zoetis.com/_assets/pdf/corporate/zoetis-2025-annual-report.pdf].

Zoetis also provides revenue guidance, with expectations of $9.825 - $10.025 billion for full year 2026 [https://news.zoetis.com/press-releases/press-release-details/2026/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx].

Zoetis is publicly traded on the NYSE under the ticker ZTS [https://investor.zoetis.com/home/default.aspx], reflecting its established market presence. While specific details on recent fundraising rounds or major acquisitions were not prominently highlighted in the provided sources, the consistent growth in revenue and net income, alongside significant investments in research and development—$698 million in 2025 [https://www.zoetis.com/_assets/pdf/corporate/zoetis-2025-annual-report.pdf]—suggest a robust financial health supporting organic growth and strategic expansions.

Additionally, Zoetis will be present at major healthcare forums such as the KeyBanc Capital Markets Healthcare Forum on March 17, the Barclays 28th Annual Global Healthcare Conference on March 10, and the Leerink Global Healthcare Conference on March 9 [https://investor.zoetis.com/events-and-presentations/event-details/2026/KeyBanc-Capital-Markets-Healthcare-Forum-2026-pkgHebAHt8/default.aspx]. These participations highlight their engagement within the broader financial and healthcare sectors.

The company also focuses on events specific to its industry, demonstrated by its participation in the Bank of America Securities 2026 Animal Health Summit on February 26 [https://investor.zoetis.com/events-and-presentations/event-details/2026/Bank-of-America-Securities-2026-Animal-Health-Summit-2026-BwBEy5NKJo/default.aspx]. Beyond these, Zoetis hosts its own quarterly corporate performance webcasts, such as the one for the Fourth Quarter and Full Year 2025 on February 12, 2026, and anticipates another for its Second Quarter performance on August 6, 2026 [https://investor.zoetis.com/events-and-presentations/event-details/2026/Zoetis-Quarterly-Corporate-Performance---Fourth-Quarter-and-Full-Year-2025/default.aspx]. These events underscore Zoetis's commitment to transparency and engagement with the investment community.